APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed   Growth in revenue of Single Pill combinations to EUR 8.8 million in Q1 2024 (3M 2023: EUR 6.6 million), also due to a competitor’s temporary inability to supply products Cooperation busines [ … ]

APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of the patent-protected medi [ … ]

Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) ha [ … ]

APONTIS PHARMA expects profitable growth again in 2024   Total sales 2023 of EUR 37.0 million exceed reduced forecast of EUR 36.1 million (2022: EUR 55.7 million) EBITDA 2023 at EUR -7.7 million before restructuring expenses (forecast: EUR -8.6 million before restructuring expenses) One-off restructuring expenses of EUR 5.6 million at the lower  [ … ]

APONTIS PHARMA expects profitable growth again in 2024   Total sales 2023 of EUR 37.0 million exceed reduced forecast of EUR 36.1 million (2022: EUR 55.7 million) EBITDA 2023 at EUR -7.7 million before restructuring expenses (forecast: EUR -8.6 million before restructuring expenses) One-off restructuring expenses of EUR 5.6 million at the lower  [ … ]

APONTIS PHARMA successfully completes performance and efficiency improvement program   New go-to-market approach comes into action earlier than planned on 1 March 2024 Headcount reduced from 185 to 110 employees Expenses at EUR 5.6 million at lower end of planning – no further burdens in financial year 2024 Savings – based on a full 12-month pe [ … ]